Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix ® 30) can improve glycaemic control in patients treated with basal insulins: A subgroup analysis of the IMPROVE™ observational study

International Journal of Clinical Practice

Volumn 63, Issue 6, 2009, Pages 966-972

  Gumprecht, J ^a   Benroubi, M ^b   Borzi, V ^c   Kawamori, R ^d   Shaban, J ^e   Shah, S ^f   Shestakova, M ^g   Wenying, Y ^h   Ligthelm, R ⁱ   Valensi, P ^j,k  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF CATANIA   (Italy)

^d JUNTENDO UNIVERSITY   (Japan)

^e WINDSOR REGIONAL HOSPITAL   (Canada)

^f Bhatia Hospital   (India)

^g N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^h CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

ⁱ EHM Clinic   (Netherlands)

^j UNIVERSITÉ PARIS 13   (France)

^k HÔPITAL JEAN VERDIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; BIPHASIC INSULIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; PATIENT SATISFACTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME; BIPHASIC INSULINS; INSULIN ASPART; INSULIN, ISOPHANE;

EID: 65649091666     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02064.x     Document Type: Article

References (22)

1. Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 6.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
3. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001 30 : 935 82.
4. Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 32 : 405 12.
5. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008 31 : 1 11.
6. Hirsch IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005 23 : 78 86.
7. Brunton S. Insulin regimens for type 2 diabetes mellitus. J Fam Pract 2006 55 : 10S 17S.
8. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 81.
9. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70-30 (The 1-2-3 study). Diabetes Obes Metab 2006 8 : 58 66.
10. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003 26 : 881 5.
11. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007 9 : 630 9.
12. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
13. Malone JK, Kerr LE, Campaigne BN et al., for the Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75-25 plus metformin or insulin glargine plus metformin: a 16-week, randomised, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004 26 : 2034 44.
14. Kann P, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006 114 : 527 32.
15. Wenying Y, Qiuhe J, Dalong Z et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008 31 : 852 6.
16. Gough S. Post-marketing surveillance: a UK-European perspective. Curr Med Res Opin 2005 21 : 565 70.
17. Ligthelm RJ, Borzì V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007 29 : 1284 92.
18. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008 62 : 1013 8.
19. Valensi P, Benroubi M, Borzi V et al., on behalf of the IMPROVE™ Study Group Expert Panel. The IMPROVE™ study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008 62 : 1809 19.
20. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006 15 : 481 91.
21. Liebl A, Prager R, Binz K et al., PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomised controlled trial. Diabetes Obes Metab 2009 11 : 45 52.
22. Barnett A, Begg A, Dyson P et al. Insulin for type 2 diabetes: choosing a second line insulin regimen. Int J Clin Pract 2008 62 : 1647 53.